BLFS | Ticker Profile - Titan Protect

BLFS

BioLife Solutions, Inc.

Healthcare · Medical Instruments & Supplies · NCM

$26.65

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.2B

Total market value of the company

Trailing P/E

N/A

Forward P/E

84.48

Based on estimated future earnings — lower means cheaper

Rev Growth

+24.7%

Year-over-year revenue change

Profit Margin

-2.9%

How much profit the company keeps from each dollar of revenue

ROE

-3.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$32.50

+22% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 10 analysts covering this stock

About BioLife Solutions, Inc.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

https://www.biolifesolutions.com

Country: United States Employees: 155 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.410

Positive but modest risk-adjusted returns

Kelly Fraction

0.0278

Modest edge detected — smaller position warranted

Calmar Ratio

0.222

Drawdown risk outweighs the returns — higher risk profile

Annual Return

8.2%

Historical annualised return based on price data

Max Drawdown

-37.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.97

Significantly more volatile than the market

52W High

$29.62

10% below the year high

52W Low

$17.86

49% above the year low

Avg Volume

489,085

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

12.1%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.24

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.99

Heavy leverage — higher financial risk if revenues decline

Current Ratio

7.30

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

5.15

Like current ratio but excludes inventory — stricter test

Gross Margin

63.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.1%

Profit from core operations before interest and tax

Free Cash Flow

$6M

Positive — the business generates more cash than it spends

Revenue (TTM)

$102M

Total revenue over the last 12 months

Net Income

$-11,215,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$34.00

Target Median

$32.50

Target Low

$30.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go